Validation of the GOLD 2017 Classification in a Chinese COPD Cohort

Juan-Juan Fu,Tao Fan,Guan-hong Li,Li-Hua Wu,Bing Mao
DOI: https://doi.org/10.1183/1393003.congress-2017.pa3616
IF: 24.3
2017-01-01
European Respiratory Journal
Abstract:Background: The 2017 GOLD report refined combined assessment and proposed pharmacologic strategy. Aims: To apply the new GOLD classification to a Chinese cohort, and to assess the concordance of current medication use according to the new assessment and levels of circulating inflammatory markers. Methods: Patients (n=222) with COPD underwent a combined assessment of symptoms (mMRC or CAT) and exacerbation history in a cross-sectional study. Medication use and medical history were recorded. Serum levels of CRP, IL-6, IL-8 and TNF-α were determined using ELISA. Patients were classified as group A, B, C and D based on the combined assessment. Clinical characteristics, medication use and levels of inflammatory markers were compared among groups. Results: In groups A, B, C and D, there were 5(2.3%), 29(13.1%), 13(5.9%) and 62(78.8%) patients respectively. Age, sex, BMI and smoking history did not differ among the groups. Patients in group B and D had higher scores of hospital depression scale than that in group C (P=0.008). Charlson comorbidity index was greater in group D than group C (P=0.007). The distribution of group A to D changed to 16(7.2%), 18(8.1%), 53(23.9%) and 135(60.8%) when symptoms were assessed using mMRC only. LAMA or ICS/LABA or triple therapy was used in 55.1%, 15.4% and 58.3% of groups B, C and D respectively. Levels of Inflammatory markers were not different among groups. Conclusion: Patients in ‘more symptoms’ groups were associated with deteriorated depression status and high comorbidity. Symptom assessment using mMRC only led to a reduction in symptom severity. A discrepancy was observed between the actual medication use and guideline recommendation while a majority of patients were undertreated.
What problem does this paper attempt to address?